Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Russell K. Pachynski, Luke Nordquist, Michael T. Schweizer, John Shen, Nabil Adra, Mehmet A. Bilen, Zachery R. Reichert, Rahul Aggarwal, Bilal A. Siddiqui, Matt Li, Dong Xu, Richard Huhn, Darryl Z. L'Heureux, Jinchun Yan, Ying Buechler, Sulan Yao, John Simitzi, Wenge Shi, Shawn Zhang, Scott T. Tagawa
Institutions: Washington University in St. Louis, Seattle Cancer Care Alliance, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Emory University, Winship Cancer Institute, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, University of California, San Francisco, The University of Texas MD Anderson Cancer Center, Ambrx (United States), Weill Cornell Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282961943